Please login to the form below
New accounts: April
The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period January 2005 to March 2005 inclusive.
The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period January 2005 to March 2005 inclusive. Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may also be involved with some of the products listed in other ways, or in domestic, overseas or international markets. To submit an entry for New Accounts, e-mail websales@pmlive.com.
|
|
 |
|
|
|
3M Health Care |
Skin portfolio |
Wound care |
The Medical Multimedia Company |
|
Abbott Laboratories |
Kaletra |
HIV |
The Medical Multimedia Company |
|
AstraZeneca (Global) |
Zoladex |
Prostate cancer |
Tonic Life Communications |
|
Baxter Healthcare |
N/A |
Haemodialysis |
The Medical Multimedia Company |
|
Boehringer Ingelheim |
Mirapexin |
Parkinson's disease |
Lowe Fusion |
|
GE Healthcare |
New product |
Nuclear medicine |
Lowe Fusion |
|
GE Healthcare |
Steripet |
Nuclear medicine |
Lowe Fusion |
|
GSK/Roche |
Bonviva |
Osteoporosis |
Virgo Health PR |
|
Janssen-Cilag |
Tramacet |
Pain |
Lowe Fusion |
|
Lilly/Boehringer Ingelheim |
Yentreve nurse programme |
Incontinence |
Medicom Group |
|
Merck KGaA |
Erbitux |
Metastatic colorectal cancer |
Chandler Chicco Agency |
|
Napp Pharmaceuticals |
N/A |
Pain |
Axon Communications |
|
National Health Service |
Primary Care managers training programme |
N/A |
Medicom Group |
|
Pfizer |
Varenicline |
Smoking cessation |
Chandler Chicco Agency |
|
PM Society |
PRIME training programme |
N/A |
Helen Lawn & Associates |
|
Replay Media |
Corporate |
N/A |
Helen Lawn & Associates |
|
Sankyo Pharmaceuticals |
Olmetec |
Cardiovascular |
Kendle Healthcare |
|
sanofi-aventis |
Fasturtec |
Hyperuricaemia |
Discovery London |
|
sanofi-aventis |
Taxotere |
Oncology |
Discovery London |
|
sanofi-aventis |
Arava |
Arthritis |
Discovery London |
|
sanofi-aventis |
Xatral |
Benign prostatic hyperplasia |
Discovery London |
|
Schering-Plough |
Subutex |
Opioid dependence |
Discovery London |
|
Schering-Plough |
Viraferon-Peg |
Hepatitis C |
Discovery London |
|
Servier |
Procoralan |
Cardiology |
Shire Health London |
|
Straken |
Tostrex |
Hypogonadism |
Medicom Group |
|
Yamanouchi |
Flomax |
Benign prostatic hyperplasia |
Shire Health London |
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- MHRA approves second COVID-19 antibody treatment
- Roche acquires test maker TIB Molbiol
- Sanofi to buy acne specialist Origimm
- Merck enters agreement with Hanmi for investigational NASH drug
- AstraZeneca blocks take-private buyout of Sobi
- Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen hands out $120m upfront for Remedy stroke drug
- Pfizer's 2021 revenue predictions soar to $82bn
- The Pharma Multi-channel Marketing Maturity Model
- Assessing the value of interim analyses in clinical trials
- Booster plans expanded to combat Omicron
PMHub
Market Access Transformation
Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
